Health technology assessment reports for oncology medications in Canada from 2018 to 2025: methodological critiques on manufacturers’ submissions and a comparison between manufacturers and Canada’s Drug Agency (CDA) analyses

20260 citationsJournal Article

Authors

Sepideh Mardani Jadid · Brighton Hospital

Mobina Dokhaei · Brighton Hospital

Naeemeh Dini · Brighton Hospital

Masoud Tajadod · Brighton Hospital

Dorsa Azizi Khezri · Brighton Hospital

Kimia Hariri · Brighton Hospital

Mitchell Levine ·

Abstract

Using MAIC or naïve ITC, submitting a dossier that includes limited clinical evidence, and surrogate outcomes are associated with a negative recommendation.

Topics & Keywords

Health Systems, Economic Evaluations, Quality of Life Economic and Financial Impacts of Cancer Statistical Methods in Clinical Trials

Publication Details

Published in: Expert Review of Pharmacoeconomics & Outcomes Research

Volume 26, Issue 3, pp. 451-463

DOI: 10.1080/14737167.2026.2632265

Field-Weighted Citation Impact: 0.00

Command Palette

Health technology assessment reports for oncology medications in Canada from 2018 to 2025: methodological critiques on manufacturers’ submissions and a comparison between manufacturers and Canada’s Drug Agency (CDA) analyses

Authors

Abstract

Topics & Keywords

Publication Details